Cassava Sciences Inc (SAVA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cassava Sciences Inc (SAVA) has a cash flow conversion efficiency ratio of -0.076x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.22 Million) by net assets ($81.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cassava Sciences Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Cassava Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Cassava Sciences Inc debt and liabilities for a breakdown of total debt and financial obligations.
Cassava Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cassava Sciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inmobiliaria Manquehue S.A
SN:MANQUEHUE
|
0.019x |
|
Nurol Gayrimenkul Yatirim Ortakligi AS
IS:NUGYO
|
0.016x |
|
Mallcom (India) Limited
NSE:MALLCOM
|
0.021x |
|
Kuantum Papers Limited
NSE:KUANTUM
|
0.115x |
|
Globe International Ltd
AU:GLB
|
0.030x |
|
MGI Digital
PA:ALMDG
|
0.008x |
|
Kestrel Group, Ltd.
NASDAQ:KG
|
-0.023x |
|
Tex Cycle Technology M Bhd
KLSE:0089
|
0.046x |
Annual Cash Flow Conversion Efficiency for Cassava Sciences Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Cassava Sciences Inc from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see Cassava Sciences Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $145.70 Million | $-116.93 Million | -0.803x | -34.49% |
| 2023-12-31 | $137.47 Million | $-82.03 Million | -0.597x | -75.15% |
| 2022-12-31 | $227.54 Million | $-77.51 Million | -0.341x | -186.46% |
| 2021-12-31 | $253.91 Million | $-30.20 Million | -0.119x | -103.73% |
| 2020-12-31 | $92.20 Million | $-5.38 Million | -0.058x | +48.69% |
| 2019-12-31 | $22.10 Million | $-2.51 Million | -0.114x | +53.19% |
| 2018-12-31 | $19.63 Million | $-4.77 Million | -0.243x | +71.38% |
| 2017-12-31 | $9.70 Million | $-8.24 Million | -0.849x | -29.37% |
| 2016-12-31 | $18.64 Million | $-12.23 Million | -0.656x | -112.94% |
| 2015-12-31 | $29.37 Million | $-9.05 Million | -0.308x | -29.31% |
| 2014-12-31 | $40.06 Million | $-9.55 Million | -0.238x | -65.75% |
| 2013-12-31 | $48.30 Million | $-6.95 Million | -0.144x | +73.65% |
| 2012-12-31 | $13.14 Million | $-7.17 Million | -0.546x | -9220.90% |
| 2011-12-31 | $44.39 Million | $-260.00K | -0.006x | -34.88% |
| 2010-12-31 | $32.93 Million | $-143.00K | -0.004x | +96.80% |
| 2009-12-31 | $108.25 Million | $-14.69 Million | -0.136x | -226.78% |
| 2008-12-31 | $104.29 Million | $11.16 Million | 0.107x | +398.57% |
| 2007-12-31 | $103.91 Million | $2.23 Million | 0.021x | +114.14% |
| 2006-12-31 | $77.92 Million | $-11.83 Million | -0.152x | -108.49% |
| 2005-12-31 | $63.36 Million | $113.23 Million | 1.787x | +612.48% |
| 2004-12-31 | $93.40 Million | $-32.57 Million | -0.349x | -30.19% |
| 2003-12-31 | $76.56 Million | $-20.51 Million | -0.268x | +13.20% |
| 2002-12-31 | $50.22 Million | $-15.50 Million | -0.309x | -63.67% |
| 2001-12-31 | $65.62 Million | $-12.37 Million | -0.189x | -100.90% |
| 2000-12-31 | $78.69 Million | $-7.39 Million | -0.094x | +68.16% |
| 1999-12-31 | $9.14 Million | $-2.69 Million | -0.295x | -- |
About Cassava Sciences Inc
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known a… Read more